Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Tae Wan Kim, Hong Joo Kim, Chang Uk Chon, Hyun Sun Won, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol. 2012;18(2):203-212.   Published online 2012 Jun 26     DOI:
Citations to this article as recorded by Crossref logo
Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center
Nuretdin Suna, Diğdem Özer Etik, Serkan Öcal, Haldun Selçuk
Experimental and Clinical Transplantation.2019;[Epub]     CrossRef
Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the UK Clinical Practice Research Datalink
Katrina Wilcox Hagberg, Vikrant V. Sahasrabuddhe, Katherine A. McGlynn, Susan S. Jick
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2016; 36(2): 187.     CrossRef
The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis
Iván Herrera, Sonia Pascual, Pedro Zapater, Fernando Carnicer, Pablo Bellot, José María Palazón
European Journal of Gastroenterology & Hepatology.2016; 28(10): 1194.     CrossRef
Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials
Maja Thiele, Agustín Albillos, Rozeta Abazi, Reiner Wiest, Lise L. Gluud, Aleksander Krag
Liver International.2015; 35(8): 2009.     CrossRef
Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?
Maja Thiele, Reiner Wiest, Lise Lotte Gluud, Agustín Albillos, Aleksander Krag
Medical Hypotheses.2013; 81(5): 871.     CrossRef